The U.S. Food and Drug Administration hopped onto Serica Technologies Inc.’s SeriScaffold product, granting the silk-based surgical mesh clearance to hit the market.
The Medford-based growth-stage device maker’s flagship product is designed to repair and remodel damaged connective tissue, avoiding the erosion and scar formation that can result from surgery.
The company believes SeriScaffold could potentially be used in the 860,000 aesthetic augmentation and reconstructive surgical procedures conducted annually in the U.S. and in other procedures, including rotator cuff and hernia repair operations.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.